Lebrikizumab and tralokinumab, IL-4/IL-13 inhibitors, show clinical efficiency in asthma and AD [84, 85] indication for the shared inflammatory mechanisms in the atopic diseases pathogenesis. Here, IL4 is linked to asthma.